MCRB, US81750R2013

Seres Therapeutics stock at EUR 2.28, USD 25.2 million market value

Published on 10/15/2026 at 22:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Nasdaq 52-week range stood at USD 2.38 to USD 29.98 on October 15, 2026. Seres Therapeutics stock costs EUR 2.28 on October 15, 2026.

Market levels and trading activity

The Nasdaq-listed company had a USD 25.2 million market value on October 15, 2026.
Its 52-week range was USD 2.38 to USD 29.98 on October 15, 2026.
Seres Therapeutics stock costs EUR 2.28 at Lang & Schwarz on October 15, 2026 at 10:32 p.m. CEST.
Trading volume was 24,613 shares against an average of 65,268 on October 15, 2026.

MCRB, US81750R2013, Illustration mit AI erstellt.

Seres Therapeutics stock was trading at EUR 2.28 at Lang & Schwarz on October 15, 2026, at 10:32 p.m. CEST. The euro quote places the company within a wide US-dollar trading range, while the Nasdaq listing provides the main comparison for US investors.

52-week range spans USD 2.38 to USD 29.98

Seres Therapeutics had a market value of USD 25.2 million on October 15, 2026. Its Nasdaq 52-week range ran from USD 2.38 to USD 29.98, putting the latest US price of USD 2.53 at the lower end of that interval.

The distance between the yearly low and high remains material for a biotechnology stock. The low-to-high spread was USD 27.60, or 1,159.66 percent measured against the USD 2.38 low. The range therefore matters more than a single intraday level when assessing the stock's recent placement.

Trading activity stays below average

Volume reached 24,613 shares on Nasdaq on October 15, 2026, compared with an average volume of 65,268 shares. That was 62.29 percent below the average, giving the day's price indication a thinner trading backdrop than the usual session.

Nasdaq price and valuation

On Nasdaq, Seres Therapeutics last traded at USD 2.53 on October 15, 2026, at 4:00 p.m. ET, up 4.55 percent from the prior close. The same quote showed a negative trailing P/E ratio of 1.06 and a market value of USD 25.2 million.

Seres Therapeutics is a biotechnology company developing microbiome-based therapies. Its business profile includes live biotherapeutic programs aimed at infectious and immune-related conditions, making clinical progress and financing capacity central valuation variables.

Comparison with peers

MCRB: plus 4.55 percent, P/E minus 1.06, market capitalization USD 25.2 million
BioLineRx (Nasdaq, USD): minus 1.20 percent, P/E minus 1.15, market capitalization USD 10.2 million
Serina Therapeutics (Nasdaq, USD): plus 4.68 percent, P/E minus 0.95, market capitalization USD 26.8 million

Price remains the clearest daily marker

The German euro quote and the US listing point to the same small-cap biotechnology profile, but they serve different trading venues and currencies. For investors following the stock from Germany, the Lang & Schwarz price is EUR 2.28 on October 15, 2026 at 10:32 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Seres Therapeutics stock.